We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
- Authors
LeBlanc, Richard; Mian, Hira; Reece, Donna; Jiandong Su; Masih-Khan, Esther; Chu, Michael; Jimenez-Zepeda, Victor; Sebag, Michael; Song, Kevin; Louzada, Martha; Kotb, Rami; Visram, Alissa; White, Darrell; Stakiw, Julie; Reiman, Antony; Aslam, Muhammad; Bergstrom, Debra; Kaedbey, Rayan; Gul, Engin; Venner, Christopher
- Abstract
Introduction: Although daratumumab-containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable. Methods and Objective: We performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark the efficacy of carfilzomib- or pomalidomide-based therapies immediately following progression on daratumumab treatment. Results: We identified 178 such patients; median number of prior lines of therapy was 3, 97% triple-class exposed, and 60% triple-class refractory. In our cohort, 75 received a subsequent carfilzomib-based therapy, 79 received a pomalidomidebased therapy, and 24 received a treatment with both immunomodulatory drug (IMiD) and proteasome inhibitor (PI) using carfilzomib and/or pomalidomide. The median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 4.5 and 14.2 months, respectively. Carfilzomib-based therapy yielded a median PFS and OS of 4.5 and 10.2 months, respectively, compared to 5.2 and 21.7 months for pomalidomide-based therapy. Patients who received both IMiD and PI with carfilzomib and/or pomalidomide had a median PFS and OS of 4.1 and 14.5 months, respectively. Conclusion: Our observations demonstrate the poor outcome of MM patients when standard regimens based on carfilzomib and/or pomalidomide are utilized directly after daratumumab-based therapy given in the relapsed setting. Novel therapies, including immune therapies, are urgently needed to improve the outcomes of these daratumumab-exposed patients.
- Subjects
MULTIPLE myeloma; DATABASES; RESEARCH teams; DARATUMUMAB; PROGRESSION-free survival
- Publication
European Journal of Haematology, 2023, Vol 111, Issue 5, p815
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.14082